Energy‐sparing by 2‐methyl‐2‐thiazoline protects heart from ischaemia/reperfusion injury. (2nd December 2021)

• Record Type: Journal Article
• Authors: Nishi, Masahiro; Ogata, Takehiro; Kobayakawa, Ko; Kobayakawa, Reiko; Matsuo, Tomohiko; Cannistraci, Carlo Vittorio; Tomita, Shinya; Taminishi, Shunta; Suga, Takaomi; Kitani, Tomoya; Higuchi, Yusuke; Sakamoto, Akira; Tsuji, Yumika; Soga, Tomoyoshi; Matoba, Satoaki
• Is Part Of: ESC heart failure. Volume 9:Number 1(2022)
• Page Start: 428
• Page End: 441
• Publication Date: 2021-12-02
• Subjects: Ischaemia/reperfusion injury -- Drug therapy -- Hypothermia -- Metabolism -- 2‐Methyl‐2‐thiazoline; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13732
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Cardiac ischaemia/reperfusion (I/R) injury remains a critical issue in the therapeutic management of ischaemic heart failure. Although mild hypothermia has a protective effect on cardiac I/R injury, more rapid and safe methods that can obtain similar results to hypothermia therapy are required. 2‐Methyl‐2‐thiazoline (2MT), an innate fear inducer, causes mild hypothermia resulting in resistance to critical hypoxia in cutaneous or cerebral I/R injury. The aim of this study is to demonstrate the protective effect of systemically administered 2MT on cardiac I/R injury and to elucidate the mechanism underlying this effect. Methods and results: A single subcutaneous injection of 2MT (50 mg/kg) was given prior to reperfusion of the I/R injured 10 week‐old male mouse heart and its efficacy was evaluated 24 h after the ligation of the left anterior descending coronary artery. 2MT preserved left ventricular systolic function following I/R injury (ejection fraction, %: control 37.9 ± 6.7, 2MT 54.1 ± 6.4, P < 0.01). 2MT also decreased infarct size (infarct size/ischaemic area at risk, %: control 48.3 ± 12.1, 2MT 25.6 ± 4.2, P < 0.05) and serum cardiac troponin levels (ng/mL: control 8.9 ± 1.1, 2MT 1.9 ± 0.1, P < 0.01) after I/R. Moreover, 2MT reduced the oxidative stress‐exposed area within the heart (%: control 25.3 ± 4.7, 2MT 10.8 ± 1.4, P < 0.01). These results were supported by microarray analysis of the mouse hearts. 2MT induced a transient, mild decrease in core body temperature (°C: −2.4 ± 1.4), which gradually recovered over several hours. Metabolome analysis of the mouse hearts suggested that 2MT minimized energy metabolism towards suppressing oxidative stress. Furthermore, 18F‐fluorodeoxyglucose‐positron emission tomography/computed tomography imaging revealed that 2MT reduced the activity of brown adipose tissue (standardized uptake value: control 24.3 ± 6.4, 2MT 18.4 ± 5.8, P < 0.05). 2MT also inhibited mitochondrial respiration and glycolysis in rat cardiomyoblasts. Conclusions: We identified the cardioprotective effect of systemically administered 2MT on cardiac I/R injury by sparing energy metabolism with reversible hypothermia. Our results highlight the potential of drug‐induced hypothermia therapy as an adjunct to coronary intervention in severe ischaemic heart disease.